Advertisement

Archives of Pharmacal Research

, Volume 34, Issue 1, pp 99–107 | Cite as

Total cholesterol, high density lipoprotein and triglyceride for cardiovascular disease in elderly patients treated with metformin

  • Hye Yeon Sin
  • Jin Yub Kim
  • Ki Hwa Jung
Drug Actions

Abstract

Metformin reduces total cholesterol level, low density lipoprotein cholesterol (LDL-C) level, blood glucose level and increases high density lipoprotein cholesterol (HDL-C) level associated with cardiovascular disease. We evaluated effect of metformin on lipid profile in Korean patients with type 2 diabetes aged 64 yeras or older. We retrospectively examined 307 outpatients treated with metformin in a hospital setting with a follow-up period of 4.7 years. Metformin was not associated with the improvement in total cholesterol level (adjusted mean difference; 30.6 mg/dl, 95% CI: 24.9 to 36.4) and HDL-C level (adjusted mean difference; 2.6 mg/dl, 95% CI: 0.09 to 4.64) but may be associated with improvement in triglyceride level (adjusted mean difference; 41.5 mg/dl, 95% CI: 24.7 to 58.3). In comparison to the placebo groups (Kooy et al., 2009), there was a 1.5-fold decrease in triglyceride level and a 2-fold decrease in HDL-C level in our study. The frequency of Scr level that increased above the defined level [Scr ≥ 1.5 mg/dl for male, ≥1.4 mg/dl for female] was 6.7% [mean difference of elevated Scr: −0.9 mg/dl, 95% CI: −0.41 to −1.44, p < 0.002]. To confirm the efficacy of metformin use on triglyceride level and HDL-C level associated with the risk of cardiovascular disease in patient with diabetes, further placebo-controlled investigations are required.

Key words

Cardiovascular disease High density lipoprotein cholesterol Triglyceride 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Bailey, C. J., Metformin: effect on micro and macrovascular complications in type2 diabetes. Cardiovasc. Drugs Ther., 22, 215–224 (2008).PubMedCrossRefGoogle Scholar
  2. Beckman, J. A., Creager, M. A., and Libby, P., Diabetes and atherosclerosis, epidemiology, pathophysiology, and management. JAMA, 287, 2570–2581 (2002).PubMedCrossRefGoogle Scholar
  3. Bristol-myers squibb company: Glucophage and Glucophage XR prescribing information.available: http://packageinserts.bms.com/pi/pi_glucophage.pdf.accessed July 03 (2009).
  4. Coresh, J., Wei, G. L., McQuillan, G., Brancati, F. L., Levey, A. S., Jones, C., and Klag, M. J., Prevalence of high blood pressure and elevated serum creatinine level in the United States. Arch. Intern. Med., 161, 1207–1216 (2001).PubMedCrossRefGoogle Scholar
  5. Corti, M. C., Guralnik, J. M., Salive, M. E., Harris, T., Field, T. S., Wallace, R. B., Berkman, L. F., Seeman, T. E., Glynn, R. J., Hennekens, C. H., and Havik, R. J., High density lipoprotein cholesterol predicts coronary heart disease mortality in older persons. JAMA, 274, 539–544 (1995).PubMedCrossRefGoogle Scholar
  6. Culleton, B. F., Larson, M. G., Evans, J. C., Wilson, P. W., Barrett, B. J., Parfrey, P. S., and Levy, D., Prevalence and correlates of elevated serum creatine levels. Arch. Intern. Med., 159, 1785–1790 (1999).PubMedCrossRefGoogle Scholar
  7. DeFronzo, R. A., Goodman, A. M., and multicenter metformin study group, Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. N. Engl. J. Med., 333, 541–549 (1995).PubMedCrossRefGoogle Scholar
  8. Di Angelantonio, E., Sarwar, N., Kaptoge, S., Ray, K. K., Thompson, A., Wood, A. M., Lewington, S., Sattar, N., Packard, C. J., Collins, R., Thompson, S. G., and Danesh, J., Major lipids, apolipoproteins, and risk of vascular disease. JAMA, 302, 1993–2000 (2009).PubMedCrossRefGoogle Scholar
  9. Hemmingsen, B., Lund, S. S., Wetterslev, J., and Vaag, A., Oral hypoglycemic agent, insulin resistance and cardiovascular disease in patients with type 2 diabetes. Eur. J. Endocrinol., 161, 1–9 (2009).PubMedCrossRefGoogle Scholar
  10. Hunt, S. A., Abraham, W. T., Chin, M. H., Feldman, A. M., Francis, G. S., Ganiats, T. G., Hessup, M., Konstam, M. A., Mancini, D. M., Michl, K., Oates, J. A., Rahko, P. S., Silver, M. A., Stvensen, L. W., and Yancy, C. W., ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult. A report of the ACC/AHA task force on practice guideline (trunk), Betheseda (MD). American College of Cardiology foundation (ACCF), August 82p, [694 references] (2005).Google Scholar
  11. Kooy, A., de Jager, J., Lehert, P., Bets, D., Wulffelé, M. G., Donker, A. J., and Stehouwer, C. D., Long term effect of metformin on metabolism and microvascullar and macrovascular disease. Arch. Intern. Med., 169, 616–625 (2009).PubMedCrossRefGoogle Scholar
  12. National kidney foundation (K/DOQI)., K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. Am. J. Kidney Dis., 45, S1–S153 [736 references] (2005).Google Scholar
  13. Nordestgaard, B. G., Benn, M., Schnohr, P., and Tybjaerg-Hansen, A., Non-fasting triglyceride and risk of MI, ischemic heart disease, and death in men and women. JAMA, 298, 299–308 (2007).PubMedCrossRefGoogle Scholar
  14. Pradhan, A. D., Everett, B. M., Cook, N. R., Rifai, N., and Ridker, P. M., Effect of initiating insulin and metformin on glycemic control and inflammatory biomarkers among patients with type 2 diabetes. JAMA, 302, 1186–1194 (2009).PubMedCrossRefGoogle Scholar
  15. Psaty, B. M. and Lumley, T., Surrogate end points and FDA approval. JAMA, 299, 1474–1476 (2008).PubMedCrossRefGoogle Scholar
  16. Roper, N. A., Bilous, R. W., Kelly, W. F., Unwin, N. C., and Connolly, V. M., Cause-specific mortality in a population with diabetes. Diabetes Care, 25, 43–48 (2002).PubMedCrossRefGoogle Scholar
  17. Ryden, L., Standl, E., Bartnik, M., Betterridge, J., Van den Berghe, G., de Boer, M. J., Cosentino, F., Jonsson, B., Laakso, M., Malmberg, K., Priori, S., Ostergren, J., Tuomilehto, J., and Thrainsdottir, I., Task force on diabetes cardiovascular diseases guideline on diabetes, pre-diabetes, and cardiovascular disease. Eur. Societ. of Cardiology (ESC), 72p [711 references] (2007).Google Scholar
  18. Selvin, E., Coresh, J., Golden, S. H., Brancati, F. L., Folsom, A. R., and Steffes, M. W., Glycemic control and coronary heart disease risk in persons with and without diabetes. Arch. Intern. Med., 165, 1910–1916 (2005).PubMedCrossRefGoogle Scholar
  19. Selvin, E., Bolen, S., Yeh, H. C., Wiley, C., Wilson, L. M., Marinopoulos, S. S., Feldman, L., Vassy, J., Wilson, R., Bass, E. B., and Brancati, F. L., Cardiovascular outcomes in trial of oral diabetes medications. Arch. Intern. Med., 168, 2070–2080 (2008).PubMedCrossRefGoogle Scholar
  20. Simmons, R. K., Sharp, S., Boekholdt, S. M., Sargeant, L. A., Khaw, K. T., Wareham, N. J., and Griffin, S. J., Evaluation of the Framingham risk score in the European prospective investigation of cancer-norfolk cohort. Arch. Intern. Med., 168, 1209–1216 (2008).PubMedCrossRefGoogle Scholar
  21. Sniderman, A. D., Scantlebury, T., and Cianflone, K., Hypertriglyceridemic hyperapo B: The unappreciated atherogenic dyslipoproteinemia in tye 2 diabetes mellitus. Ann. Intern. Med., 135, 447–459 (2001).PubMedGoogle Scholar
  22. Sone, H., Mizuno, S., Fujii, H., Yoshimura, Y., Yamasaki, Y., Ishibashi, S., Katayama, S., Saito, Y., Ito, H., Ohashi, Y., Akanuma, Y., and Yamada, N., Is the diagnosis of metabolic syndrome useful for predicting cardiovascular disease in Asian diabetic patients? Diabetes Care, 28, 1463–1471 (2005).PubMedCrossRefGoogle Scholar
  23. Stern, M. P., The effect of glycemic control on the incidence of macrovascular complications of type2 diabetes. Arch. Fam. Med., 7, 155–162 (1998).PubMedCrossRefGoogle Scholar
  24. Summary of revisions for the 2009: clinical practice recommendations. Diabetes Care, 32Suppl, S3–S5 (2009).CrossRefGoogle Scholar
  25. Turner, R. C., Millns, H., Neil, H. A., Stratton, I. M., Manley, S. E., Matthews, D. R., and Holman, R. R., Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United kingdom prospective diabetes study (UKPDS23). BMJ, 316, 823–828 (1998).PubMedGoogle Scholar
  26. Turner, R. C., Cull, C. A., Frighi, V., and Holman, R. R., Glycemic control with diet, sulfonylurea, metformin, or insulin inpatients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA, 281, 2005–2012 (1999).PubMedCrossRefGoogle Scholar
  27. Warnick, G. R. and Wood, P. D., National cholesterol education program recommendations for measurement of high-density lipoprotein-cholesterol: executive summary. The national cholesterol education program working group on lipoprotein measurement. Clin. Chem., 41, 1427–1433 (1995).PubMedGoogle Scholar
  28. Weverling-Rijnsburger, A. W., Jonkers, I. J., Exel, E., Gussekloo, J., and Westendorp, R. G., High density vs low density lipoprotein cholesterol as the risk factor for coronary artery disease and stroke in old age. Arch. Intern. Med., 163, 1549–1554 (2003).PubMedCrossRefGoogle Scholar

Copyright information

© The Pharmaceutical Society of Korea and Springer Netherlands 2011

Authors and Affiliations

  1. 1.Department of PharmacyGangneung Asan HospitalGangneungKorea
  2. 2.EndocrinologyGangneung Asan HospitalGangneungKorea
  3. 3.College of PharmacyDuksung Women’s UniversitySeoulKorea

Personalised recommendations